PAXIP1 antisense RNA 2 (PAXIP1-AS2)

PAXIP1 antisense RNA 2 (PAXIP1-AS2) is a long non-coding RNA transcribed antisense to the PAXIP1 gene. It modulates the translesion DNA synthesis (TLS) pathway by influencing the expression of regulatory proteins including RAD18 and DNA polymerase η, thus affecting how cells tolerate and repair DNA damage. Overexpression of PAXIP1-AS2 or knockdown of related proteins (such as TENT4A or CYLD) leads to decreased levels of RAD18 and DNA polymerase η, consequently reducing TLS efficiency. Dysregulation of TLS-regulating genes, including PAXIP1-AS2 and its network, is frequently observed in endometrial cancer genomes and may contribute to cancer progression by promoting genomic instability. PAXIP1-AS2 is not a protein or classical receptor, but an antisense lncRNA that exerts its effects at the transcriptional and post-transcriptional level, providing a potential target for future therapeutic approaches and biomarker development in oncology.

For experimental modulation: Overexpression or knockdown of PAXIP1-AS2 alters DNA repair/tolerance via the TLS pathway. Not applicable for drugs, since no direct drug interventions reported.